Search Result

Results for "

IACS

" in MedChemExpress (MCE) Product Catalog:

標的別:	Apoptosis (3) c-Fms (1) DNA/RNA Synthesis (2) Drug Intermediate (1) Epigenetic Reader Domain (4) Indoleamine 2,3-Dioxygenase (IDO) (3) Lactate Dehydrogenase (1) MAP3K (1) Mitochondrial Metabolism (2) Oxidative Phosphorylation (2) Phosphatase (2) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) SHP2 (2) STING (5)
研究分野別:	Cancer (22) Endocrinology (1) Neurological Disease (1)

製品番号	製品名	Target	研究分野	構造式

HY-112037

IACS-010759 Maximum Cited Publications 26 Publications Verification IACS-10759	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research .

HY-130115A

IACS-8803 disodium 1 Publications Verification	STING	Cancer
IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .

HY-102000B

IACS-9571 hydrochloride 1 Publications Verification ASIS-P040 hydrochloride	Epigenetic Reader Domain	Cancer
IACS-9571 (ASIS-P040) hydrochloride is a potent and selective inhibitor of TRIM24 and BRPF1, with an IC₅₀ of 8 nM for TRIM24, and K_ds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively .

HY-112037A

IACS-010759 hydrochloride Maximum Cited Publications 26 Publications Verification IACS-10759 hydrochloride	Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis	Cancer
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research .

HY-137092

IACS-13909 3 Publications Verification	SHP2 Phosphatase	Cancer
IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC₅₀ of 15.7 nM and a K_d of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers .

HY-176798

NCI-006	Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis	Cancer
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC₅₀ = 0.06 μM; LDHB IC₅₀ = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .

HY-130115

IACS-8803	STING	Cancer
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .

HY-132901

IACS-15414	SHP2 Phosphatase	Cancer
IACS-15414 is a potent and orally bioavailable SHP2 inhibitor with an IC₅₀ value of 122 nM.

HY-155089

IACS-52825	MAP3K	Neurological Disease
IACS-52825 is a potent and selective DLK inhibitor with K_d of 1.3 nM, useful for the study of chemotherapy-induced peripheral neuropathy .

HY-112164

IACS-8968 1 Publications Verification IDO/TDO Inhibitor	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IACS-8968 (IDO/TDO Inhibitor) is a dual IDO and TDO inhibitor, with pIC₅₀s of 6.43 for IDO and <5 for TDO, respectively.

HY-102000

IACS-9571 ASIS-P040	Epigenetic Reader Domain	Cancer
IACS-9571 is a potent and selective inhibitor of TRIM24 and BRPF1, with IC₅₀ of 8 nM for TRIM24, and K_ds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.

HY-130115B

IACS-8803 diammonium 1 Publications Verification	STING	Cancer
IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .

HY-130116

IACS-8779	STING	Cancer
IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy .

HY-153243

IACS-9439	c-Fms	Cancer
IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a K_i value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research .

HY-120936

IACS-4759	DNA/RNA Synthesis	Cancer
IACS-4759 is a potent and selective MTH1 (MutT homolog 1) inhibitor with an IC₅₀ of 0.6 nM. IACS-4759 has anti-cancer effects .

HY-130116A

IACS-8779 disodium	STING	Cancer
IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .

HY-112164B

IACS-8968 S-enantiomer IDO/TDO Inhibitor (S-enantiomer)	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC₅₀s of 6.43 for IDO and <5 for TDO, respectively.

HY-112164A

IACS-8968 R-enantiomer IDO/TDO Inhibitor (R-enantiomer)	Indoleamine 2,3-Dioxygenase (IDO)	Cancer
IACS-8968 (R-enantiomer) is the R-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC₅₀s of 6.43 for IDO and <5 for TDO, respectively.

HY-102000A

IACS-9571 TFA ASIS-P040 TFA	Epigenetic Reader Domain	Cancer
IACS-9571 (trifluoroacetate) is a potent and selective inhibitor of TRIM24 and BRPF1, with IC₅₀ of 8 nM for TRIM24, and K_d of 31 nM and 14 nM for TRIM24 and BRPF1, respectively.

HY-164981

p-SCN-Bn-DOTA(tBu)4	Drug Intermediate	Cancer
p-SCN-Bn-DOTA(tBu)4 is the derivative of DOTA (HY-W053583). p-SCN-Bn-DOTA(tBu)4 is the component of the Gd(III)-DOTA-IAC, which is a targeted magnetic resonance imaging (MRI) contrast agent for αvβ3 integrin receptor .

HY-181555

IACS-56676	Ras	Endocrinology Cancer
IACS-56676 is a selective NRAS ^G12D inhibitor with a target IC₅₀ of 0.031 μM. IACS-56676 stabilizes the p-loop, maintains key interactions with Asp12, Gly60 and Asp69, and achieves selectivity against wild-type KRAS through substitution targeting Leu95. IACS-56676 can be used in the research of melanoma, hematologic malignancies and thyroid cancer .

HY-123599

IACS-4619	DNA/RNA Synthesis	Cancer
IACS-4619 (compound 4) is a highly selective 2-aminopyrimidine-based MTH1 (MutT homolog 1) inhibitor (IC₅₀=0.2 nM). IACS-4619 inhibits MTH1 by blocking its hydrolysis of oxidized purine nucleotides such as 8-oxo-dGTP, thereby preventing MTH1 from inhibiting the incorporation of oxidized nucleotides into DNA. IACS-4619 significantly inhibits endogenous MTH1 activity in MTH1-overexpressing U2OS cells, but without antiproliferative or cytotoxic effects on various human cancer and normal cell lines. IACS-4619 can be used in oncology research related to the MTH1 target .

HY-102000BR

IACS-9571 hydrochloride (Standard) ASIS-P040 hydrochloride (Standard)	Reference Standards Epigenetic Reader Domain	Cancer
IACS-9571 hydrochloride (Standard) is the analytical standard of IACS-9571 hydrochloride (HY-102000B). This product is intended for research and analytical applications. IACS-9571 (ASIS-P040) hydrochloride is a potent and selective inhibitor of TRIM24 and BRPF1, with an IC₅₀ of 8 nM for TRIM24, and Kds of 31 nM and 14 nM for TRIM24 and BRPF1, respectively .

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
タイトル			国或いは地域 *
お名前 *			組纖名 *
デパートメント *
メールアドレス *			製品名 *
製品番号			カスタマ需要量 *
電話番号 *
必ず会社名を記載ください。個人への返信は行いません。
備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

お名前
メール *

	Sorry, but the email address you supplied was invalid.

IACS

阻害剤およびアゴニスト